Trial reportDiabetes2014
Limited recovery of β-cell function after gastric bypass despite clinical diabetes remission.
Trial report in Diabetes, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 84 citations in OpenAlex.
- Effects of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on β-Cell Function at 1 Year After Surgery: A Systematic Review.The Journal of clinical endocrinology and metabolism · 2022Pooled it
- Metabolomic profiling identifies complex lipid species and amino acid analogues associated with response to weight loss interventions.PloS one · 2021Pooled it
- Comparative impact of Roux-en-Y gastric bypass, sleeve gastrectomy or diet alone on beta-cell function in insulin-treated type 2 diabetes patients.Scientific reports · 2024Trial
- Effect of Laparoscopic Sleeve Gastrectomy on Static and Dynamic Measures of Glucose Homeostasis and Incretin Hormone Response 4-Years Post-Operatively.Obesity surgery · 2020Trial
- Trial
- Insulin Sensitivity and Secretion in Obese Type 2 Diabetic Women after Various Bariatric Operations.Obesity facts · 2016Trial
- Trial
- Attenuated improvements in adiponectin and fat loss characterize type 2 diabetes non-remission status after bariatric surgery.Diabetes, obesity & metabolism · 2014Trial
- Metabolic and bariatric surgeries in individuals with obesity and BMI of 30-35 kg/m2: systematic review.Revista da Associacao Medica Brasileira (1992) · 2025Article
- Determination of autoantibodies in type 2 diabetes: one simple way to improve classification. Reply by Laferrère to Ludvigsson J [letter].Diabetologia · 2023Article
- Glucagon-like peptide-1 effect on β-cell function varies according to diabetes remission status after Roux-en-Y gastric bypass.Diabetes, obesity & metabolism · 2022Article
- Effects of a 13-Week Personalized Lifestyle Intervention Based on the Diabetes Subtype for People with Newly Diagnosed Type 2 Diabetes.Biomedicines · 2022Article
- Role of the Gut in the Temporal Changes of β-Cell Function After Gastric Bypass in Individuals With and Without Diabetes Remission.Diabetes care · 2022Article
- Preoperative Plasma Aldosterone Predicts Complete Remission of Type 2 Diabetes after Bariatric Surgery.Obesity facts · 2022Article
- Determinants of type 2 diabetes remission after bariatric surgery in obese Japanese patients: a retrospective cohort study.Diabetology international · 2021Article
- Preintervention Clinical Determinants and Measured β-Cell Function As Predictors of Type 2 Diabetes Remission After Roux-en-Y Gastric Bypass Surgery.Diabetes care · 2021Article
- Metabolic effects of duodenojejunal bypass surgery in a rat model of type 1 diabetes.Surgical endoscopy · 2021Article
- Diabetes Remission After Gastric Bypass: To Be or Not to Be Dependent on Weight Loss.The Journal of clinical endocrinology and metabolism · 2021Article
- Glucose Homeostasis, Fetal Growth and Gestational Diabetes Mellitus in Pregnancy after Bariatric Surgery: A Scoping Review.Journal of clinical medicine · 2020Article
- The Effects of Bariatric Surgery on Islet Function, Insulin Secretion, and Glucose Control.Endocrine reviews · 2019Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
The mechanisms responsible for the remarkable remission of type 2 diabetes after Roux-en-Y gastric bypass (RYGBP) are still puzzling. To elucidate the role of the gut, we compared β-cell function assessed during an oral glucose tolerance test (OGTT) and an isoglycemic intravenous glucose clamp (iso-IVGC) in: 1) 16 severely obese patients with type 2 diabetes, up to 3 years post-RYGBP; 2) 11 severely obese normal glucose-tolerant control subjects; and 3) 7 lean control subjects. Diabetes remission was observed after RYGBP. β-Cell function during the OGTT, significantly blunted prior to RYGBP, normalized to levels of both control groups after RYGBP. In contrast, during the iso-IVGC, β-cell function improved minimally and remained significantly impaired compared with lean control subjects up to 3 years post-RYGBP. Presurgery, β-cell function, weight loss, and glucagon-like peptide 1 response were all predictors of postsurgery β-cell function, although weight loss appeared to be the strongest predictor. These data show that β-cell dysfunction persists after RYGBP, even in patients in clinical diabetes remission. This impairment can be rescued by oral glucose stimulation, suggesting that RYGBP leads to an important gastrointestinal effect, critical for improved β-cell function after surgery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.